Related references
Note: Only part of the references are listed.Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
Ing S. Tiong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia
Yuting Tang et al.
FASEB JOURNAL (2021)
NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization
Marketa Sasinkova et al.
SCIENTIFIC REPORTS (2021)
Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC
Geri Traver et al.
CANCER LETTERS (2021)
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
Ilaria Gionfriddo et al.
LEUKEMIA (2021)
Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells
Sudhakiranmayi Kuravi et al.
MOLECULAR CANCER RESEARCH (2021)
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
Vincenzo Maria Perriello et al.
CANCERS (2021)
Conformational consequences of NPM1 rare mutations: An aggregation perspective in Acute Myeloid Leukemia
Sara La Manna et al.
BIOORGANIC CHEMISTRY (2021)
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S. Tiong et al.
BLOOD ADVANCES (2021)
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia
Ganqian Zhu et al.
NATURE COMMUNICATIONS (2021)
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
Mael Heiblig et al.
CANCERS (2021)
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
Hyunsoo Cho et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML
Bing Z. Carter et al.
BLOOD (2021)
Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia
Louise Pettersson et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Szymon Klossowski et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia
Atom J. Wang et al.
LEUKEMIA (2020)
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Hannah J. Uckelmann et al.
SCIENCE (2020)
Dactinomycin in acute myeloid leukemia with NPM1 mutations
Guillaume Beziat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Nucleophosmin in Its Interaction with Ligands
Ilaria Cela et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
Silke Kapp-Schwoerer et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia
G. D. Bailey et al.
SCIENTIFIC REPORTS (2020)
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju et al.
BLOOD ADVANCES (2020)
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
Gunnar Juliusson et al.
BLOOD ADVANCES (2020)
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A. Lachowiez et al.
BLOOD ADVANCES (2020)
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
Erik Delsing Malmberg et al.
LEUKEMIA & LYMPHOMA (2019)
Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis
Matthew A. Loberg et al.
LEUKEMIA (2019)
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
Paolo Sportoletti et al.
LEUKEMIA (2019)
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
Fabio Forghieri et al.
Oncotarget (2019)
Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis
Yan Huang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia
Sanjay S. Patel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern
Luca Vincenzo Cappelli et al.
LEUKEMIA (2019)
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita
Daphna Nachmani et al.
NATURE GENETICS (2019)
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa et al.
CANCERS (2019)
The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia
Dimitrios Papaioannou et al.
NATURE COMMUNICATIONS (2019)
Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia
Lu Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome
Emily F. Mason et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
When the good go bad: Mutant NPM1 in acute myeloid leukemia
Preethi Kunchala et al.
BLOOD REVIEWS (2018)
N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy
A. De Cola et al.
CANCER LETTERS (2018)
Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf
Enrico Luchinat et al.
FEBS JOURNAL (2018)
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Carmen Martinez-Losada et al.
HAEMATOLOGICA (2018)
NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
Pedro Henrique Prata et al.
HAEMATOLOGICA (2018)
Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies
Min Zhang et al.
LEUKEMIA RESEARCH (2018)
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Carmen Martinez-Losada et al.
HAEMATOLOGICA (2018)
NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents
Pedro Henrique Prata et al.
HAEMATOLOGICA (2018)
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Lorenzo Brunetti et al.
CANCER CELL (2018)
Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival
Wu Zhang et al.
THERANOSTICS (2018)
Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3A mutations
Xinrui Yang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
Alexander Hoellein et al.
BLOOD ADVANCES (2018)
Subtype-specific patterns of molecular mutations in acute myeloid leukemia
D. Rose et al.
LEUKEMIA (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia
Jay L. Patel et al.
LEUKEMIA RESEARCH (2017)
Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ
A. Di Matteo et al.
ONCOGENESIS (2017)
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
Oliver M. Dovey et al.
BLOOD (2017)
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
Prajwal Boddu et al.
BLOOD ADVANCES (2017)
Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro
Xia Zhang et al.
ANTI-CANCER DRUGS (2017)
Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia
Ali I. Nabbouh et al.
CANCER (2017)
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+cytogenetically normal acute myeloid leukemia
Mario Tiribelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
Tamara Alpermann et al.
HAEMATOLOGICA (2016)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
Tamara Alpermann et al.
HAEMATOLOGICA (2016)
Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission
Michal Karas et al.
ANTICANCER RESEARCH (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques
Anita Chopra et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2016)
Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia
Vibeke Andresen et al.
CELL DEATH & DISEASE (2016)
A redox mechanism underlying nucleolar stress sensing by nucleophosmin
Kai Yang et al.
NATURE COMMUNICATIONS (2016)
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Michael W. M. Kuhn et al.
CANCER DISCOVERY (2016)
Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells
Min Huang et al.
ONCOTARGET (2016)
Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression
Shuaishuai Zhang et al.
JOURNAL OF CANCER (2016)
Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia
Hanna Grauers Wiktorin et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1)
Narsimha Reddy Penthala et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
Maria Paola Martelli et al.
BLOOD (2015)
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
Andrew Wei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia
Yoko Ogawara et al.
CANCER RESEARCH (2015)
Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation
Sha Yi et al.
ANNALS OF HEMATOLOGY (2015)
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J. J. Cornelissen et al.
LEUKEMIA (2015)
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML
Violaine Havelange et al.
BLOOD (2014)
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse
Max Hubmann et al.
HAEMATOLOGICA (2014)
Structural polymorphism in the N-terminal oligomerization domain of NPM1
Diana M. Mitrea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model
Paolo Sportoletti et al.
BLOOD (2013)
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
Jochen Greiner et al.
BLOOD (2013)
Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission
Norbert-Claude Gorin et al.
HAEMATOLOGICA (2013)
Mutations in the Nucleolar Phosphoprotein, Nucleophosmin, Promote the Expression of the Oncogenic Transcription Factor MEF/ELF4 in Leukemia Cells and Potentiates Transformation
Koji Ando et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations
Dana Dvorakova et al.
LEUKEMIA & LYMPHOMA (2013)
Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA
Sara Chiarella et al.
NUCLEIC ACIDS RESEARCH (2013)
Identification of Two Novel NPM1 Mutations in Patients with Acute Myeloid Leukemia
Yongbum Jeon et al.
ANNALS OF LABORATORY MEDICINE (2013)
The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia
Aziz Nazha et al.
FRONTIERS IN ONCOLOGY (2013)
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: A GOELAMS study
Romain Guieze et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
Friederike Schneider et al.
ANNALS OF HEMATOLOGY (2012)
Immune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation
R. Casalegno-Garduno et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
Maria Stefania De Propris et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Knockdown of NPM1 by RNA Interference Inhibits Cells Proliferation and Induces Apoptosis in Leukemic Cell Line
Feng-Xian Qin et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
NPM1/B23: AMultifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling
Mikael S. Lindstrom
BIOCHEMISTRY RESEARCH INTERNATIONAL (2011)
Core transcription factors, Oct4, Sox2 and Nanog, individually form complexes with nucleophosmin (Npm1) to control embryonic stem (ES) cell fate determination
Helena Johansson et al.
AGING-US (2010)
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice
Maria Paola Martelli et al.
BLOOD (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nucleolar protein B23 has molecular chaperone activities
Attila Szebeni et al.
PROTEIN SCIENCE (2010)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)
Arcangelo Liso et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias
C. G. Mullighan et al.
LEUKEMIA (2007)
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML):: biologic and clinical features
Brunangelo Falini et al.
BLOOD (2007)
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML
Brunangelo Falini et al.
BLOOD (2006)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
K Döhner et al.
BLOOD (2005)
Role of nucleophosmin in embryonic development and tumorigenesis
S Grisendi et al.
NATURE (2005)
Share Paper
